You are here

  • Home
  • Archive
  • Volume 4, Issue Suppl 1
  • 90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study

Citation Tools

Article menu

Download PDFPDF

Poster Session
New therapies and therapeutic targets – SLE
90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Chamberlain C, Colman P, Ranger A, et al
90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study
Lupus Science & Medicine 2017;4:doi: 10.1136/lupus-2017-000215.90